When Sleep Therapy Devices Go Wrong: Philips DreamStation Ventilator Recall Explained
Sleep apnea affects millions. For many, devices like CPAPs or BiPAPs are lifelines — nightly helpers that keep airways open, ensure proper oxygenation, and protect against serious health risks. So when devices meant to heal can potentially misbehave, it’s a serious matter. Recently, Philips Respironics initiated a recall for certain DreamStation Auto CPAP / Auto […]
When Your CGM Says “No Active Sensor” but Isn’t Warning You: Dexcom’s App Correction & Its Impact
Imagine relying on a continuous glucose monitor (CGM) app to track your blood sugar—only to have the sensor fail and the app quietly stop sending data. You see the “No active sensor” screen and assume everything is OK or that it’s just a small glitch. But it’s not. Because the app didn’t alert you to […]
FDA’s Real-Time Adverse Event Reporting Dashboard for Cosmetics: A New Era of Transparency
Published: September 2025 Imagine you bought a new shampoo, hair dye, or moisturizer. A few days later, you notice a rash, excessive itching, or even worse. What would you do? Report it—but often, you might wonder whether your report ever makes a difference. With the FDA’s launch of its new dashboard for real-time adverse event […]
Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry
Understanding the Guidance: What, Why, How In September 2025, the U.S. Food and Drug Administration (FDA) issued a nonbinding guidance for industry titled “Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.” U.S. Food and Drug Administration This document gives detailed recommendations for sponsors developing therapeutic protein biosimilars, especially how to design […]
FDA’s Guidance on Alternative Tools for Assessing Drug Manufacturing Facilities: What It Means for Pharma
In September 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance document titled “Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications.” This guidance redefines how regulators and industry navigate facility assessments for pending drug applications—including NDAs, ANDAs, and BLAs. The new framework signals FDA’s intent to use more flexible, risk-based […]